Core Insights - Entera Bio Ltd. is advancing its pipeline of oral peptide therapies, with significant developments in programs targeting osteoporosis, hypoparathyroidism, and metabolic syndromes [2][3][13] Group 1: Product Development Updates - EB613, the first oral anabolic peptide tablet for osteoporosis, has a streamlined Phase 3 protocol submitted to the FDA, with results expected in late 2028, one year earlier than previously anticipated [3][4] - The FDA has aligned with Entera on using bone mineral density (BMD) as the primary endpoint for EB613, marking a significant milestone in the drug's development [3] - EB612, an oral long-acting PTH replacement tablet for hypoparathyroidism, is set to file an IND application in late 2026, in collaboration with OPKO [5][10] - EB618, an oral dual GLP-1/glucagon peptide tablet for metabolic syndromes, has completed PK/PD validation, with Phase 1 initiation expected following injectable formulation data [6] Group 2: Financial Performance - As of December 31, 2025, Entera reported cash and cash equivalents of $14.9 million, with $7.8 million in restricted cash for OPKO collaboration [8] - The net loss for the year ended December 31, 2025, was $11.4 million, consistent with the previous year, reflecting ongoing investment in R&D and operational activities [9][12] - Research and development expenses increased to $6.0 million in 2025, primarily due to regulatory preparations for EB613 and internal program costs [11] Group 3: Clinical Data and Efficacy - Phase 2 data for EB613 demonstrated significant increases in bone indices after six months of treatment, comparable to injectable therapies [10] - New analyses showed EB613's effectiveness in increasing BMD in younger postmenopausal women, highlighting its potential as a preventive treatment for osteoporotic fractures [10]

Core Viewpoint - Entera Bio Ltd. has submitted a streamlined Phase 3 protocol to the FDA for EB613, an oral anabolic treatment for postmenopausal women with osteoporosis, aiming for faster patient access and potential commercialization [6][9]. Company Overview - Entera Bio is focused on developing oral peptide and protein replacement therapies, leveraging its proprietary N-Tab® technology platform [11]. - The company's lead product, EB613, is the first oral anabolic treatment for osteoporosis, designed to be taken once daily [11]. Clinical Development - The Phase 3 study will evaluate the percentage change in total hip bone mineral density (BMD) from baseline to 12 months, with a target enrollment of 750 women [8]. - Topline data is expected in the second half of 2028, which is approximately one year earlier than previously anticipated [2][3]. - The study is designed to demonstrate increases in total hip BMD comparable to those reported for Forteo® at 12 months, which is associated with a 60% to 80% relative reduction in vertebral fracture risk [8]. Regulatory Submission - Entera has submitted a clinical amendment to the FDA, including a statistical analysis plan and an open-label extension study synopsis [6][7]. - The open-label extension study will randomize participants to receive EB613 for either 12 or 24 months or transition to a standard anti-resorptive agent [3]. Market Context - Osteoporosis is a significant public health issue, with over 2 million fractures annually in the US, and the total medical cost of osteoporotic fractures projected to rise from $57 billion in 2018 to $95 billion by 2040 [10]. - Postmenopausal women are particularly at risk, with one in three women suffering an osteoporosis-related fracture after age 50 [10]. Product Efficacy - EB613 has shown rapid dose-proportional increases in bone formation markers and significant increases in lumbar spine, total hip, and femoral neck BMD in a previous Phase 2 study [9][11]. - The product aims to democratize access to anabolic treatment for osteoporosis, addressing a significant unmet medical need [9].

Core Insights - Entera Bio Ltd. has submitted a clinical amendment to the FDA for EB613, an oral anabolic treatment for osteoporosis, with a streamlined Phase 3 protocol and anticipates feedback within 60 days [1][2][5] - The Phase 3 trial will evaluate the efficacy of EB613 in increasing total hip bone mineral density (BMD) over 12 months, with a target enrollment of 750 postmenopausal women [3][5] - The company expects topline data in the second half of 2028, one year earlier than previously anticipated, and plans to conduct a 12-month open-label extension study in parallel with the NDA review [1][5] Company Overview - Entera Bio is focused on developing oral peptide and protein replacement therapies, with EB613 being the first oral anabolic tablet for osteoporosis [9] - The company utilizes a proprietary technology platform (N-Tab) to create innovative oral therapies, aiming to transform the standard of care in various medical fields [9] - Entera's pipeline includes other oral therapies for conditions such as hypoparathyroidism, obesity, and metabolic syndromes, indicating a broad focus on unmet medical needs [9] Industry Context - Osteoporosis is a significant public health issue, leading to over 2 million fractures annually in the US, with a projected increase in medical costs from $57 billion in 2018 to $95 billion by 2040 [8] - The disease predominantly affects postmenopausal women, with one in three women and one in five men likely to suffer an osteoporosis-related fracture after age 50 [8] - Current anabolic therapies for osteoporosis are administered via injection, limiting patient access; Entera's oral formulation aims to democratize treatment and improve patient compliance [6][8]

Core Viewpoint - Entera Bio Ltd. has announced that several members of its Board of Directors, including the Chairman, have made open market purchases of the Company's ordinary shares, indicating confidence in the Company's future prospects [1][2]. Group 1: Board Purchases - The purchases were made by Geno J. Germano (Chairman), Steven D. Rubin, Haya Taitel, and Sean Ellis, all Directors of the Company [2]. - These transactions were conducted at prevailing market prices and are reported in filings with the U.S. Securities and Exchange Commission [2]. Group 2: Company Overview - Entera Bio is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs [4]. - The Company utilizes a proprietary technology platform (N-Tab®) and has a pipeline of first-in-class oral peptide programs targeting PTH(1-34), GLP-1, and GLP-2 [4]. - The most advanced product candidate, EB613, is being developed as the first oral osteoanabolic treatment for post-menopausal women with low bone mineral density and high-risk osteoporosis [4]. - A Phase 2 study of EB613 met primary and secondary endpoints, demonstrating its potential effectiveness [4]. - Entera is also developing the first oral oxyntomodulin for obesity and metabolic syndromes, and the first oral GLP-2 peptide for rare malabsorption conditions in collaboration with OPKO Health [4].

Core Insights - Entera Bio Ltd. has appointed Geno J. Germano as the new Chairman of the Board, effective February 4, 2026, succeeding Gerald Lieberman [1] - The company is advancing two oral PTH peptide programs into clinical testing in 2026, including a Phase 3 study for EB613 in osteoporosis and a first-in-human study for Long-Acting Oral PTH in hypoparathyroidism [2] Leadership Changes - Geno J. Germano brings over three decades of leadership experience in the pharmaceutical and life sciences sectors, having held senior roles at Pfizer, including Group President of Pfizer's Global Innovative Pharmaceutical Business, managing a portfolio worth approximately $14 billion [4] - The CEO of Entera, Miranda Toledano, expressed gratitude for the contributions of the outgoing Chairman and emphasized the importance of Germano's experience in scaling therapeutic platforms [3] Product Development - Entera's lead clinical asset, EB613, is positioned to transform osteoporosis treatment by providing an oral anabolic therapy, which could facilitate earlier intervention in treatment paradigms [3] - The company is also developing other oral peptide therapies, including EB612 for hypoparathyroidism and a dual-targeted GLP-1/glucagon peptide for obesity and metabolic syndromes [5]

Core Insights - Entera Bio Ltd. has appointed Geno J. Germano as Chairman of the Board, effective February 4, 2026, succeeding Gerald Lieberman [1] - The company is advancing two oral PTH peptide programs into clinical testing in 2026, including a Phase 3 study for EB613 in osteoporosis and a first-in-human study for Long-Acting Oral PTH in hypoparathyroidism [2] Company Developments - Entera's lead clinical asset, EB613, is positioned to transform osteoporosis treatment by providing an oral anabolic therapy, which could broaden its use among patients [3] - The company has established a foundation for its oral peptide pipeline and is transitioning to late-stage clinical testing, with Germano's leadership expected to enhance its development and commercialization efforts [3][4] Leadership Background - Geno J. Germano brings over 30 years of experience in the pharmaceutical and life sciences sectors, having held senior roles at Pfizer, including leading a $14 billion innovative medicines portfolio [4] - Germano's previous board experience includes roles at various biotechnology companies, indicating a strong background in guiding clinical-stage firms [4] Product Pipeline - Entera is focused on developing oral peptide and protein replacement therapies, leveraging its proprietary N-Tab® technology platform [5] - The company's most advanced product, EB613, is being developed as the first oral treatment for post-menopausal women with low bone mineral density and high-risk osteoporosis [5] - Additional programs include an oral PTH(1-34) tablet for hypoparathyroidism and an oral oxyntomodulin for obesity and metabolic syndromes [5]

Core Insights - Entera Bio Ltd. is set to achieve significant milestones in Q1 2026, focusing on the development of oral peptide therapies for osteoporosis and hypoparathyroidism [2][3] Group 1: Corporate Milestones - The company plans to submit its final Phase 3 protocol for EB613 to the FDA in Q1 2026, following a favorable FDA ruling on December 19, 2025 [4] - Results from the Phase 1 bridging study of Next-Gen EB613 are expected by the end of Q1 2026, indicating progress in the development of this next-generation candidate [5] - Entera aims to accelerate its hypoparathyroidism program in 2026, leveraging robust preclinical data for a long-acting PTH analog [6] Group 2: Product Development - EB613 is being developed as the first oral PTH(1-34) anabolic tablet treatment specifically for post-menopausal women with osteoporosis [4][6] - The company is also advancing its EB612 program, which focuses on an oral long-acting PTH(1-34) peptide tablet for patients with hypoparathyroidism [6] - Entera is exploring strategic partnerships to optimize the development and commercialization of its oral peptide programs [6] Group 3: Company Vision - Entera Bio is committed to addressing significant unmet medical needs through innovative oral peptide therapies, aiming to transform the standard of care in various therapeutic areas [7]

Core Insights - Entera Bio Ltd. is set to submit its final Phase 3 protocol for EB613 to the FDA in Q1 2026, following a favorable ruling in December 2025 [1][3] - The company is advancing its Next-Generation EB613 Phase 1 bridging study, with results anticipated by the end of Q1 2026 [1][4] - Entera is accelerating its oral hypoparathyroidism tablet program with long-acting PTH variants and is engaged in strategic partnership discussions to enhance its pipeline [1][5] Company Overview - Entera Bio is focused on developing oral peptide and protein replacement therapies for significant unmet medical needs, utilizing its proprietary N-Tab™ technology [6] - The company's lead product, EB613, is an oral PTH(1-34) anabolic tablet aimed at post-menopausal women with osteoporosis, having met primary and secondary endpoints in a Phase 2 study [6] - Entera is also developing EB612, an oral long-acting PTH(1-34) peptide tablet for hypoparathyroidism, and other oral peptide therapies targeting obesity and rare malabsorption conditions [6]

Core Insights - Entera Bio Ltd. has received FDA qualification for total hip bone mineral density (BMD) as a validated regulatory endpoint for osteoporosis drug development, which supports the company's strategy for its product EB613 [1][2] - The FDA's position may simplify the regulatory pathway for Entera, allowing a single Phase 3 study with total hip BMD as the primary endpoint to support a New Drug Application (NDA) for EB613 [2] Company Overview - Entera Bio is focused on developing oral peptide and protein replacement therapies, aiming to transform the standard of care for significant unmet medical needs [7] - The company's lead product candidate, EB613, is being developed as the first oral, once-daily anabolic tablet treatment for post-menopausal women with low BMD and high-risk osteoporosis [4][7] Industry Context - Osteoporosis affects over 200 million women globally, with a significant number remaining undertreated; no new osteoporosis drug has been approved by the FDA since 2019 [2][5] - Osteoporosis is a major public health issue, leading to over 2 million fractures annually in the US, with projected medical costs for osteoporotic fractures expected to rise from $57 billion in 2018 to $95 billion by 2040 [5] Product Development - EB613 has shown efficacy in a Phase 2 study, meeting all biomarker and BMD endpoints without significant safety concerns, indicating its potential as a novel treatment option [4] - The development of validated surrogate endpoints like BMD may facilitate faster drug development and address the ethical challenges associated with osteoporosis clinical trials [6]

Summary of Entera Bio Conference Call Company Overview - **Company**: Entera Bio - **Focus**: Development of first-in-class oral peptides, specifically targeting osteoporosis and metabolic diseases [2][34] Key Programs - **EB613**: - First and only osteoanabolic bone-building tablet treatment for postmenopausal women with osteoporosis [2][34] - Recently received FDA green light for registrational phase three study [2][34] - Aims to address the treatment gap in osteoporosis, where less than 25% of women receive treatment post-fracture [8][34] - **Other Programs**: - Long-acting PTH variants for hyperparathyroidism, with preclinical data expected by end of 2025 [3][34] - Dual agonist GLP-1 glucagon tablet treatment, IND filing planned for first half of 2026 [3][34] - GLP-2 tablet for short bowel syndrome, exploring additional indications [3][34] Clinical Development Insights - **Phase Two Data**: - EB613 showed significant improvements in bone mineral density (BMD) across spine, hip, and femoral neck [15][19] - The same 2.5 mg dose will be used in phase three trials [15][19] - **Phase Three Trial**: - Planned as a 24-month multinational study with at least 20% U.S. patient representation [29][31] - Aims to start in the first half of 2026 [31][34] Regulatory and Market Context - **FDA Engagement**: - Entera has had multiple productive meetings with the FDA, clarifying requirements for NDA submission [7][12] - The FDA's acceptance of total hip bone mineral density as a surrogate endpoint is a significant advancement for EB613 [4][10] - **Market Opportunity**: - Osteoporosis has seen little innovation in recent years, with the last approved drug being Evanity in 2019 [8][34] - Entera aims to fill this gap with a novel oral treatment that is easier for patients to use [34] Investment Considerations - **Valuation**: - Entera is positioned as an attractive investment opportunity due to its innovative approach and the potential to change osteoporosis treatment paradigms [34] - The company is focused on closing the treatment gap in osteoporosis, which is a significant unmet medical need [34] Additional Insights - **Geographic Strategy**: - The decision to include 20% U.S. patients is strategic, aiming to align with regulatory expectations while managing costs [29][30] - The company is also exploring markets in Europe and Asia, particularly in regions with high osteoporosis prevalence [30][34] - **Future Milestones**: - Anticipated phase one data for next-generation EB613 in Q1 2026 [32][34] - Plans to report on a third variant of long-acting PTH for hypoparathyroidism preclinically [32][34] This summary encapsulates the key points discussed during the conference call, highlighting Entera Bio's strategic direction, clinical advancements, and market positioning.